James J. Harding

Associate Professor of Medicine
Medicine

James J. Harding serves as Associate Professor at Cornell University.

593 publications
18,398 citations
55 h-index
Medicine
Top Papers (1)
2021-12-13 · The Lancet Oncology · Hepatology
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
James J HardingAssociate Professor of Medicine · Medicine
94.5x expected for field · 1,117 citations
Recent Papers (15)
2026-08-17 · ESMO Gastrointestinal Oncology · Hepatology
A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma
James J. HardingAssociate Professor of Medicine · Medicine
2026-08-01 · JCO Precision Oncology · Surgery
Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma
James J. HardingAssociate Professor of Medicine · Medicine
2026-07-01 · Journal of Hepatology · Surgery
Systemic therapy of biliary tract cancer: The road to personalised strategies
James J. HardingAssociate Professor of Medicine · Medicine
2026-06-26 · Clinical Cancer Research · Surgery
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
James J. HardingAssociate Professor of Medicine · Medicine
2026-05-27 · Journal of Clinical Oncology · Surgery
Association of genomic and clinical factors with outcomes with front-line chemoimmunotherapy in patients with advanced biliary tract cancer.
James J. HardingAssociate Professor of Medicine · Medicine
2026-05-27 · Journal of Clinical Oncology · Surgery
Tracking genomic evolution in ERBB2 -altered biliary tract cancer through longitudinal tumor profiling.
James J. HardingAssociate Professor of Medicine · Medicine
2026-04-16 · Cancer Research Communications · Oncology
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
James J. HardingAssociate Professor of Medicine · Medicine
2026-03-25 · Nature Medicine · Oncology
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial
James J. HardingAssociate Professor of Medicine · Medicine
2026-02-19 · Clinical Cancer Research · Surgery
Shaping the Future of HER2-Directed Therapy in Biliary Tract Cancer
James J. HardingAssociate Professor of Medicine · Medicine
2026-01-10 · Journal of Clinical Oncology · Surgery
Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): Post hoc analysis of the HERIZON-BTC-01 trial.
James J. HardingAssociate Professor of Medicine · Medicine
2025-11-20 · JAMA Oncology
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer
James J. HardingAssociate Professor of Medicine · Medicine
2025-11-17 · Annals of Surgical Oncology
ASO Visual Abstract: Outcomes of First-versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma
James J. HardingAssociate Professor of Medicine · Medicine
2025-10-19 · Annals of Surgical Oncology · Surgery
Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma
James HardingAssociate Professor of Medicine · Medicine
2025-10-01 · JCO Precision Oncology · Surgery
Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival
James J. HardingAssociate Professor of Medicine · Medicine
2025-09-30 · Clinical Cancer Research · Surgery
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
James J. HardingAssociate Professor of Medicine · Medicine